graph EGM comparisons
pembrolizumab alonetitlepembrolizumab plus SoCtitlepembrolizumab (10mg/kg)titlepembrolizumab (2mg/kg)titlepembrolizumab and pemetrexed plus platintitleStandard of Care (SoC)titleplacebo plus SoCtitledocetaxeltitlepemetrexed plus platintitleKEYNOTE-042 (PDL1>50%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 299/300KEYNOTE-042 (PDL1>20%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 413/405KEYNOTE-024 (PDL1>50%), 2016 NCT02142738 mNSCLC - L1 - PDL1 positive 154/151KEYNOTE-042 (PDL1>1%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 637/637KEYNOTE-010 (P:10 mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 346/343KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 151/152KEYNOTE-010 (P: 2mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 344/343KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 139/152KEYNOTE-021, 2016 NCT02039674 non squamous - mNSCLC - L1 - Wild Type (WT) 60/63KEYNOTE-189, 2018 NCT02578680 non squamous - mNSCLC - L1 - Wild Type (WT) 410/206KEYNOTE-407, 2018 NCT02775435 squamous - mNSCLC - L1 - all population 278/281

Pathology:  mNSCLC - L1 - PDL1 positive;   mNSCLC - L2 - PDL1 positive;   non squamous - mNSCLC - L1 - Wild Type (WT);   squamous - mNSCLC - L1 - all population; 

mNSCLC - L1 - PDL1 positivemNSCLC - L2 - PDL1 positivenon squamous - mNSCLC - L1 - Wild Type (WT)squamous - mNSCLC - L1 - all population
KEYNOTE-042 (PDL1>50%), 2019KEYNOTE-042 (PDL1>20%), 2019KEYNOTE-024 (PDL1>50%), 2016KEYNOTE-042 (PDL1>1%), 2019KEYNOTE-010 (P:10 mg/kg), 2016KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg), 2016KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016KEYNOTE-021, 2016KEYNOTE-189, 2018KEYNOTE-407, 2018
pembrolizumab alone4T1T1T1T1
pembrolizumab plus SoC2T1T1
pembrolizumab (10mg/kg)2T1T1
pembrolizumab (2mg/kg)2T1T1
pembrolizumab and pemetrexed plus platin1T1
Standard of Care (SoC)0T0T0T0T0
placebo plus SoC0T0T0
docetaxel0T0T0T0T0
pemetrexed plus platin0T0